| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/01/2007 | WO2007025254A2 Investigation and treatment of cancer using a g-protien coupled eicosnoid receptor |
| 03/01/2007 | WO2007025238A2 Use of fructose-based therapies for the treatment of cancer |
| 03/01/2007 | WO2007025229A2 Compositions and their uses directed to hsp27 |
| 03/01/2007 | WO2007025216A2 Stem cell fusion model of carcinogenesis |
| 03/01/2007 | WO2007025049A2 Aptamers that bind thrombin with high affinity |
| 03/01/2007 | WO2007024991A2 Inhibition of mrna interferase-induced apoptosis in bak-deficient and bak-and bax-deficient mammalian cells |
| 03/01/2007 | WO2007024976A2 Virus coat protein/receptor chimeras and methods of use |
| 03/01/2007 | WO2007024941A2 Polyvalent vaccine |
| 03/01/2007 | WO2007024741A2 Methods for treatment of thiol-containing compound deficient conditions |
| 03/01/2007 | WO2007024723A2 Methods and compositions for treating gastrointestinal radiosensitivity in a subject |
| 03/01/2007 | WO2007024708A2 Rna containing modified nucleosides and methods of use thereof |
| 03/01/2007 | WO2007024207A1 Enhanced zein reduction in transgenic corn seed |
| 03/01/2007 | WO2007024008A1 Preventive or therapeutic agent for side effect based on cytotoxicity of anticancer therapy containing apoptosis inhibition activity-enhancing protein fnk or nucleic acid encoding the same |
| 03/01/2007 | WO2007023880A1 Chemokine production inhibitor |
| 03/01/2007 | WO2007023725A1 Gene vaccine |
| 03/01/2007 | WO2007023479A2 Treatment of central nervous system injury |
| 03/01/2007 | WO2007023287A1 Vectors and uses thereof |
| 03/01/2007 | WO2007008485A3 Prevention of chronic rejection in solid organ transplantation |
| 03/01/2007 | WO2006124897A3 Methods and compositions for improving cognition |
| 03/01/2007 | WO2006121960A3 Methods and sequences to suppress primate huntington gene expression |
| 03/01/2007 | WO2006119965A3 Growth factor mutants with altered biological attributes |
| 03/01/2007 | WO2006076251A3 Efficient gene suppression using a transfer rna promoter in herpes virus vectors to deliver small interference rnas |
| 03/01/2007 | WO2005089224A3 iRNA AGENTS TARGETING VEGF |
| 03/01/2007 | WO2005010143A3 Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences |
| 03/01/2007 | US20070050857 Method of treatment and prophylaxis |
| 03/01/2007 | US20070050856 Use of protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 03/01/2007 | US20070049550 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies |
| 03/01/2007 | US20070049549 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070049548 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070049547 Methods for use in modulating miR-122a |
| 03/01/2007 | US20070049546 Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals |
| 03/01/2007 | US20070049545 Antisense modulation of fibroblast growth factor receptor 3 expression |
| 03/01/2007 | US20070049544 Antisense IAP nucleobase oligomers and uses thereof |
| 03/01/2007 | US20070049543 Controlling gene expression; enzyme inhibitors |
| 03/01/2007 | US20070049542 exposing the bacterial cells to a growth-inhibiting amount of an antisense oligonucleotide compound, composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit; Escherichia coli, Salmonella |
| 03/01/2007 | US20070049541 Administering oligonucleotide containing optimal nucleotide binding site for the transcription factor for therapy of disease associated with hyper-activated signal transduction pathways, particularly malignancy |
| 03/01/2007 | US20070049540 Oligonucleotide inhibiting the expression of star-binding protein (sbp) gene and method therefor |
| 03/01/2007 | US20070049539 Rsk inhibitors and therapeutic uses thereof |
| 03/01/2007 | US20070049533 Analogs of peptides corresponding to class I major histocompatibility complex (MHC)-restricted T-cell epitopes that contain amino acid substitutions of norleucine and/or norvaline; intranodal administration a an immunopotentiating agent |
| 03/01/2007 | US20070049532 Selecting by phage display a peptide that binds to nerve growth factor (NGF), and preparing a fusion protein with an Fc domain; biological half-life increases |
| 03/01/2007 | US20070048862 Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines |
| 03/01/2007 | US20070048822 activating tyrosine phosphorylation of ErbB4 in an ErbB4-expressing cell by administering to the cell a polypeptide comprising the amino acid sequence of neuregulin 3 |
| 03/01/2007 | US20070048811 Tumor suppressor designated TS10q23.3 |
| 03/01/2007 | US20070048780 Genome sequences and nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells transformed by the vectors; kits for diagnosing infection and vaccines |
| 03/01/2007 | US20070048772 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 03/01/2007 | US20070048737 Calcium phosphate ceramics and particles for in vivo and in vitro transfection |
| 03/01/2007 | US20070048322 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 03/01/2007 | US20070048302 Interleukin-2 (IL-2); treating metastatic cancer, autoimmune disorders, and viral infections such as HIV by administering a peptide that peptide binds to the IL-2 beta chain |
| 03/01/2007 | US20070048299 Methods of inducing an immune response |
| 03/01/2007 | US20070048297 Human secreted proteins |
| 03/01/2007 | US20070048294 Method for inhibiting telomerase activity |
| 03/01/2007 | US20070048293 Manipulation of PTEN in T cells as a strategy to modulate immune responses |
| 03/01/2007 | US20070048287 Molecular antigen array |
| 03/01/2007 | US20070048286 Method of treating dopaminergic and GABA-nergic disorders |
| 03/01/2007 | US20070048285 Self-inactivating retroviral vector |
| 03/01/2007 | US20070048284 Cardiac arrhythmia treatment methods |
| 03/01/2007 | US20070048283 Exposing to immunogenic portion of protein and/or encoding nucleotide homologenous to sequence 20 or 22b; eliciting response to 74P3B3 protein; pancreatic cancer |
| 03/01/2007 | US20070048281 Vaccination with a synergistic combination of a Hepatitis C Virus E1 vaccine and an antiviral agent, such as an interferon; improved immunostimulation |
| 03/01/2007 | US20070048259 Cytokine zalpha11 ligand |
| 03/01/2007 | US20070048254 Generation of dendritic cells |
| 03/01/2007 | US20070048248 ARC186 aptamer PEG conjugate; transplant rejection; angioplasty; restenosis; specificity and affinity of the aptamer can be tightly controlled and allows the generation of leads; no toxicity or immunogenicity; chemical stability |
| 03/01/2007 | DE102005039154A1 Bioabbaubare Polymere für den Transport von Nukleinsäuren in Zellen Biodegradable polymers for the delivery of nucleic acids into cells |
| 03/01/2007 | CA2620874A1 Polyvalent vaccine |
| 03/01/2007 | CA2619950A1 Methods and compositions for investigation and treatment of cancer using a g-protein coupled eicosanoid receptor |
| 03/01/2007 | CA2619481A1 Methods for the treatment of anxiety and for identification of anxiolytic agents |
| 03/01/2007 | CA2617782A1 Aptamers that bind thrombin with high affinity |
| 03/01/2007 | CA2583501A1 Enhanced zein reduction in transgenic corn seed |
| 02/28/2007 | EP1757937A2 Antagonists of HMG1 for treating inflammatory conditions |
| 02/28/2007 | EP1757703A2 Self-inactivating retroviral vector |
| 02/28/2007 | EP1757702A1 Self-inactivating gammaretroviral vector |
| 02/28/2007 | EP1757696A2 Group B streptococcus proteins, and their use |
| 02/28/2007 | EP1757695A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757694A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757689A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 02/28/2007 | EP1757621A2 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/28/2007 | EP1757618A2 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 02/28/2007 | EP1757617A1 Ret Ligand (RetL) for stimulating neural and renal growth |
| 02/28/2007 | EP1757312A1 Freeze-dried composition of inactivated virus envelope with membrane fusion activity |
| 02/28/2007 | EP1757302A1 Adiponectin expression inducer and utilization of the same |
| 02/28/2007 | EP1757295A1 Peripheral-Type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 02/28/2007 | EP1756318A2 Aptamer-toxin molecules and method for using same |
| 02/28/2007 | EP1756288A2 Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
| 02/28/2007 | EP1756158A1 Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon |
| 02/28/2007 | EP1755670A2 Methods for treating vascular disease |
| 02/28/2007 | EP1755641A2 Agonists and antagonists of p28, ebi3 and wsx/tccr for treating immune disorders |
| 02/28/2007 | EP1755640A1 Hybrid recombinases for genome manipulation |
| 02/28/2007 | EP1755567A2 Drug delivery product and methods |
| 02/28/2007 | EP1755400A2 Aav mediated gene delivery to cochlear cells |
| 02/28/2007 | EP1337258A4 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 02/28/2007 | EP1240317B1 Nucleic acid vaccination |
| 02/28/2007 | EP1239776B1 Surgical needle with weeping tip |
| 02/28/2007 | EP1224310B1 Recombinant adenoviruses preparation and adenovirus banks |
| 02/28/2007 | EP1073737B1 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 02/28/2007 | EP1067968B1 Methods for evaluating a compound for its effect on skin |
| 02/28/2007 | EP0945506B1 Proteine avec une activite de suppression du vieillissement |
| 02/28/2007 | EP0833840B1 Hypoxia inducible factor-1 and method of use |
| 02/28/2007 | EP0758390B1 Angiostatin and method of use for inhibition of angiogenesis |
| 02/28/2007 | EP0726948B1 Method of inducing and maintaining neuronal cells |
| 02/28/2007 | CN1922332A Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 02/28/2007 | CN1922197A Targeted delivery of rna interference molecules |